March 1, 2019 06:39 AM EST
R&D

Af­ter thy­roid eye drug scores in PhI­II test, Hori­zon Phar­ma read­ies mar­ket­ing ap­pli­ca­tion

Natalie Grover

Reporter

Less than two years af­ter Hori­zon Phar­ma $HZNP pro­cured phase III-ready thy­roid eye dis­ease (TED) drug tepro­tu­mum­ab for $145 mil­lion up­front by ac­quir­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times